Status:

COMPLETED

NA-AION Risk Factors: New Perspectives

Lead Sponsor:

Rigshospitalet, Denmark

Collaborating Sponsors:

Velux Fonden

Fight for Sight

Conditions:

Non-arteritic Ischemic Optic Neuropathy

Optic Disk Drusen

Eligibility:

All Genders

11+ years

Brief Summary

The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with...

Detailed Description

Non-arteritic anterior ischemic optic neuropathy (NA-AION) is the most common acute optic neuropathy in the middle-aged and elderly population and can also occur in children and young adults. NA-AION ...

Eligibility Criteria

Inclusion

  • Diagnosis of first episode of NA-AION in study eye with symptom onset within 1 month prior
  • Subject age: Age \>10
  • NA-AION diagnosis requires:
  • disc edema seen by site PI or by referring doctor
  • visual field defect in the study eye consistent with NA-AION and mean deviation worse than 3.0 dB using the study visual field examination protocol
  • relative afferent pupillary defect (unless the fellow eye had previous NA-AION or other optic nerve or retinal disease that is not exclusionary)

Exclusion

  • Previous episode of NA-AION in the study eye only
  • Intraocular pressure of \>21 mm Hg in the study eye
  • Clinical or pathological evidence of giant cell arteritis
  • Diseases that may affect the optic nerve: glaucoma, multiple sclerosis, Alzheimer disease, and Parkinson disease. Evidence of optic disc drusen and optic nerve hypoplasia are not exclusion criteria given they are important parts of the study. We will not exclude significant retinal diseases, since they may be related to underlying etiologies giving rise to ODD, such as macular degeneration, retinal dystrophies, but eyes with significant retinal diseases will be analyzed separately.

Key Trial Info

Start Date :

August 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 31 2024

Estimated Enrollment :

179 Patients enrolled

Trial Details

Trial ID

NCT05305079

Start Date

August 1 2021

End Date

August 31 2024

Last Update

November 22 2024

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Stanford Medicine

Palo Alto, California, United States, 94305

2

UCSF Medical Center

San Francisco, California, United States, 94143

3

University og Colorado

Boulder, Colorado, United States, 80309

4

Massachusetts Eye and Ear

Boston, Massachusetts, United States, 02114